The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / B Cell-Directed Therapy May Delay RA Development in High-Risk Patients

B Cell-Directed Therapy May Delay RA Development in High-Risk Patients

February 6, 2019 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A single infusion of 1,000 mg of rituximab may significantly delay the onset of clinical signs and symptoms of arthritis in subjects at high risk of developing seropositive rheumatoid arthritis (RA), according to the exploratory, randomized, double-blind, placebo-controlled PRAIRI (prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease) study.1 The results were published in the February 2019 issue of Annals of the Rheumatic Diseases, and the initial presentation of the abstract was made during the 2016 ACR/ARHP Annual Meeting.2

You Might Also Like
  • Cardiovascular Disease Risk High in RA Patients
  • Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis
  • Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment
Also By This Author
  • Sharing Knowledge to Support Care: A Conversation with ACR Communications & Marketing Committee Member Suleman Bhana, MD, FACR

“We have created the first experimental evidence in humans that B cells play a critical role in the pathogenesis of RA during the preclinical stage of the disease,” says the study’s lead author Paul Peter Tak, MD, PhD, FMedSci, professor of medicine in the Division of Clinical Immunology and Rheumatology at the Academic Medical Center of the University of Amsterdam, The Netherlands.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“These findings also support future studies aimed at secondary prevention of RA, including by the use of targeted treatments,” Dr. Tak says.3

Previous research identified rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPAs) in the peripheral blood of individuals less than 10 years before they develop autoantibody positive RA.4,5 B cells are known to be efficient antigen-presenting cells that produce autoantibodies and may activate T cells in the context of co-stimulatory signals, producing a variety of cytokines.6

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A New Target for Early RA
The PRAIRI study explored biomarkers predictive of arthritis development and investigated the effects of B cell-directed therapy in subjects at risk of developing autoantibody positive RA who had not experienced inflammatory arthritis.

The findings are based on results from 81 subjects with arthralgia and without evidence of clinical arthritis in 66 joints examined. These patients were recruited from seven rheumatology outpatient clinics across The Netherlands between January 2010 and December 2013. The patients tested positive for IgM-RF, as well as ACPA (a-CCP2; Immunoscan CCPlus [Euro Diagnostica No RA-96plus] ELISA tests), and had never experienced inflammatory arthritis or been treated with a disease-modifying anti-rheumatic drug (DMARD). The subjects all had C-reactive protein (CRP) levels greater than 0.6 mg/L at screening (the lower limit of detection of the high-sensitivity CRP assay) or subclinical synovitis, as determined by ultrasound or MRI using gadolinium performed in the context of routine clinical care.

The subjects were randomized in a 1:1 ratio to receive either 1,000 mg of rituximab or placebo intravenously. Patients also received 100 mg methylprednisolone prior to treatment to prevent infusion-related adverse events. Randomization was stratified by age (older or younger than 40 years), as well as sex.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: B cells, early RA, Rheumatoid Arthritis (RA), rituximab, seropositive RA

You Might Also Like:
  • Cardiovascular Disease Risk High in RA Patients
  • Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis
  • Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment
  • B Cell Receptor Clones May Predict RA Onset

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)